drug pricing regulation

Government and payer limits on drug prices, such as Medicare price negotiation under the IRA.

Exposure · 25 companies

Show
8-K events
Match any selected event
8-K event types
More events

Only filters 8-Ks. Other selected forms stay visible.

  • ABBV AbbVie

    Exposed“Pricing and reimbursement pressure in the U.S. and internationally could reduce revenue and earnings.”

    Latest 10-QQ3 FY2026Positive ·

    Skyrizi and Rinvoq more than offset Humira erosion; lower acquired R&D and impairment charges amplify the earnings rebound.

    • Revenue$17.4BYoY +10.3%
    • Net income$4.2Bvs $186.0M year ago
  • AMGN Amgen

    Exposed“CMS has set Medicare Part D prices for ENBREL, effective January 1, 2026, and Otezla, effective January 1, 2027, in each case at significantly lower prices that are expected to negatively impact their profitability in Medicare.”

    Latest 10-QQ3 FY2026 ·

    Repatha, UPLIZNA and IMDELLTRA demand more than offsets biosimilar erosion in Prolia and XGEVA.

    • Revenue$10.4BYoY +8.5%
    • Net income$3.9BYoY +20.1%
  • APMD Apnimed, Inc.

    Exposed“Third-party payors, however, are increasingly challenging pharmaceutical prices and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy.”

    Latest 424B4final IPO prospectusBankruptcy / going concernAccounting issueCEO/CFO change ·

    Develops Oxnimbi, a once-nightly sleep apnea pill; $192M all-primary raise funds regulatory work and launch if approved.

  • ASPE Aspen Neuroscience, Inc.

    Exposed“Adoption or expansion of price controls and cost-containment measures could further limit our net revenue and results.”

    Latest 424B4final IPO prospectusBankruptcy / going concernPre-revenue ·

    Develops patient-derived Parkinson’s cell therapy; $141M all-primary raise backs sasineprocel’s move toward Phase 3

  • ATTO Attovia Therapeutics, Inc.

    Exposed“U.S. pricing risks include Medicare negotiation and inflation rebates under the IRA, ACA-related changes, and other federal and state drug-pricing initiatives; the filing also flags OBBBA-related changes and announced Most-Favored-Nation pricing initiatives.”

    Latest 424B4final IPO prospectusPositivePre-revenue ·

    Develops immune-disease biologics using ATTOBODY; $289M all-primary raise backs clinical validation of itch treatment ATTO-1310.

  • BLSM BlossomHill Therapeutics, Inc.

    Exposed“Pricing pressure, payor restrictions, and changes to U.S. drug-pricing and healthcare policies could further constrain commercial returns.”

    Latest 424B4final IPO prospectusBankruptcy / going concernPre-revenue ·

    Develops small-molecule cancer drugs; $150M all-primary raise funds trials led by BH-30643 for treatment-resistant lung cancer.

  • BMY Bristol-Myers Squibb

    Exposed“BMS faces intensifying pricing, reimbursement and market-access pressure in the U.S. and internationally, with potential effects on revenue and margins.”

    Latest 10-QQ3 FY2026MixedImpairment / charge ·

    Eliquis drove growth as generics eroded Revlimid and Pomalyst; pipeline licensing charges weighed on earnings.

    • Revenue$13.1BYoY +6.9%
    • Net income$2.2BYoY −1.8%
  • BRVE Braveheart Bio, Inc.

    Exposed“The Trump Administration has issued executive orders and supported proposed regulatory initiatives in 2025 that could have a significant impact on the prices that we, or any collaborators, may receive for any approved products.”

    Latest 424B4final IPO prospectusPositiveImpairment / chargePre-revenueRelated-party dependence ·

    Develops BHB-1893, an oral cardiac myosin inhibitor for hypertrophic cardiomyopathy; $383M all-primary raise funds Phase 3 trials.

  • CI Cigna Group

    Exposed“These initiatives include contract renewals, investment in a rebate-free model and recontracting around affordability and government programs, including the Inflation Reduction Act.”

    Latest 10-QQ3 FY2026MixedRestructuring ·

    Rebate-free investment and contract renewals squeeze Evernorth’s pharmacy-benefit earnings; specialty care provides an offset.

    • Revenue$73.7BYoY +5.6%
    • Net income$1.4BYoY −22.8%
  • CVS CVS Health

    Exposed“Pharmacy & Consumer Wellness: Q3 revenue and operating income reflected regulatory-related drug price reductions, generic introductions and reimbursement pressure, partly offset by favorable drug mix, brand inflation, prescription volume and Rite Aid contributions.”

    Latest 10-QQ3 FY2026Mixed ·

    Planned split separates Aetna and Caremark from CVS Pharmacy as insurance profitability improves and pharmacy pricing pressure persists.

    • Revenue$108.4BYoY +5.4%
    • Net income$2.2Bvs −$4.0B year ago
  • ELV Elevance Health

    Exposed“Other exposures include PBM legislation affecting rebates, reporting and Medicare Part D compensation; No Surprises Act disputes; mental-health-parity requirements; litigation and government reviews; cyber, privacy, technology and data-integrity risks; competition; and potential goodwill or intangible-asset impairment.”

    Latest 8-KGuidance reaffirmed ·

    FY2026 outlook reaffirmed for investor meetings: EPS of at least $22.00 diluted and $29.00 adjusted.

  • ETRA Electra Therapeutics, Inc.

    Exposed“U.S. drug-pricing and healthcare reforms, Medicare negotiation and rebates, and foreign price controls, reimbursement reviews, and health technology assessments could reduce access or commercial returns.”

    Latest 424B4final IPO prospectusMixedBankruptcy / going concernPre-revenue ·

    Develops antibodies to remove disease-driving immune cells; $350M all-primary raise funds ipsoprubart’s registrational trials

  • GILD Gilead Sciences

    Exposed“Gilead expects IRA provisions to increase payment and rebate obligations and affect prices and profitability, potentially extending to other payer segments.”

    Latest 10-QQ3 FY2026Impairment / charge ·

    Acquisition charges and the EVOKE-03 write-off drove a YTD loss despite stronger Biktarvy and Yeztugo sales.

    • Revenue$8.3BYoY +6.8%
    • Net income$2.4BYoY −20.4%
  • INVA Innoviva, Inc.

    Exposed“The Inflation Reduction Act adds direct exposure: RELVAR/BREO’s negotiated Medicare maximum fair price is scheduled to take effect **January 1, 2027**, and ANORO’s negotiated pricing is expected to take effect in **2028**.”

    Latest 10-QQ3 FY2026Positive ·

    XACDURO and GIAPREZA lift U.S. hospital sales; Armata markdowns overwhelm stronger operating earnings

    • Revenue$106.1MYoY −1.6%
    • Net income−$73.9Mvs $89.9M year ago
  • JNJ Johnson & Johnson

    Exposed“The federal Inflation Reduction Act of 2022 (IRA) includes provisions that effectively authorize the government to establish prices for certain high-spend single-source drugs and biologics reimbursed by the Medicare program, starting in 2026 for Medicare Part D drugs and 2028 for Medicare Part B drugs.”

    Latest 10-QQ3 FY2026MixedRestructuringImpairment / chargeLegal / investigation ·

    TREMFYA and oncology growth offset STELARA’s biosimilar erosion, but a proposed talc-settlement charge nearly wiped out earnings.

    • Revenue$25.4BYoY +5.9%
    • Net income$210.0MYoY −95.9%
  • LLY Eli Lilly and Company

    Exposed“Restrictive or unfavorable pricing, coverage, or reimbursement determinations for our medicines or product candidates by governments, regulatory agencies, courts, or private actors have and may continue to adversely impact our business and financial results.”

    Latest 10-QQ3 FY2026PositiveImpairment / charge ·

    Mounjaro and Zepbound volume growth outweighed lower prices, while acquired research charges constrained profit growth.

    • Revenue$24.4BYoY +38.6%
    • Net income$6.5BYoY +15.5%
  • MCK McKesson Corporation

    Exposed“The business also remains exposed to evolving drug-pricing policy, the federal 340B program and government healthcare funding.”

    Latest 10-QQ2 FY2027Restructuring ·

    Precision Medicine Group and Spectrum Vision acquisitions expand specialty care as separation costs squeeze Medical-Surgical profit.

    • Revenue$111.0BYoY +7.6%
    • Net income$1.2BYoY +9.7%
  • MRK Merck & Co.

    Exposed“The IRA also increases manufacturer liability under Medicare Part D from 2025, applies inflation-based penalties, and enables government price setting for Medicare drugs.”

    Latest 8-KLeadership change ·

    Douglas M. Baker Jr. succeeds Thomas H. Glocer as independent lead director Jan. 1, 2027, ahead of Glocer’s May 2027 board retirement.

  • PFE Pfizer

    Exposed“Any significant efforts at the federal or state levels to reform the healthcare system by changing the way healthcare is provided or funded or to expand controls on drug pricing, implement international reference pricing, including Most-Favored-Nation (MFN) drug pricing, or impact government reimbursement and access to medicines and vaccines on public and private insurance plans or consumer purchasing platforms could have a material impact on us.”

    Latest 8-KCEO/CFO change ·

    Interim CFO Cecile Guegan appointed permanent CFO and EVP, effective Nov. 1.

  • REGN Regeneron Pharmaceuticals

    Exposed“The agreements are expected to reduce prices and reimbursement for certain products; in return, qualifying products are not expected to face Section 232 tariffs through January 2029, subject to conditions that include continued U.S. manufacturing and R&D investment.”

    Latest 10-QQ3 FY2026Positive ·

    Dupixent growth and richer Sanofi profit sharing more than offset EYLEA erosion, deepening reliance on the partnership.

    • Revenue$5.1BYoY +36.3%
    • Net income$1.9BYoY +33.5%
  • RZRA Rezera Inc.

    Exposed“Prescription drug pricing in the U.S. is subject to significant political, legislative, and regulatory scrutiny.”

    Latest S-1/Aamended IPO prospectusBankruptcy / going concernAccounting issueCEO/CFO change ·

    Develops oral anti-inflammatory drugs; IPO funds a pivotal ruvonoflast trial in peripheral artery disease, its first test in these patients.

  • SCTX Scribe Therapeutics, Inc.

    Exposed“Healthcare pricing policies, including Medicare negotiation and potential most-favored-nation pricing, could pressure future prices and market opportunity.”

    Latest 424B4final IPO prospectusMixedBankruptcy / going concernCustomer concentration ·

    Develops CRISPR medicines to lower cholesterol; $129M all-primary raise funds STX-1150 trials and pipeline development.

  • SDGR Schrödinger, Inc.

    Exposed“Medicare drug-price negotiation is expanding under the IRA, alongside inflation rebates and other pricing measures; federal, state, and international reimbursement controls may limit prices or access.”

    Latest 10-QQ3 FY2026 ·

    Structure Therapeutics milestone drove revenue growth; hosted migration obscured stronger software contracting.

    • Revenue$64.5MYoY +18.7%
    • Net income−$37.7MYoY −15.0%
  • VOGX Vogenx, Inc.

    Exposed“Drug-price controls, including IRA negotiation and rebate provisions, evolving federal actions, and foreign price restrictions could limit future pricing and profitability.”

    Latest 424B4final IPO prospectusPositiveBankruptcy / going concernRestatementAccounting issue ·

    Developing oral mizagliflozin for post-bariatric hypoglycemia; $81.3M gross raise funds Phase 2 trials.

  • WWB WINDWARD BIO GROUP AG

    Exposed“Evolving U.S. and EU drug-pricing, reimbursement, and health-technology-assessment policies add uncertainty.”

    Latest 424B4final IPO prospectusPositivePre-revenue ·

    Develops long-acting antibodies for asthma and other inflammatory diseases; $175M raise funds trials led by WIN378’s potential twice-yearly dosing

Feedback